Molecules generated by Computer-Aided Drug Design often lack synthesizability to be valuable because Computer-Aided Synthesis Planning (CASP) and CASP-based approximated synthesizability scores have rarely been used as generation objectives, despite facilitating the in-silico generation of synthesizable molecules. Published scores approximate a general notion of CASP-based synthesizability with nearly unlimited building block resources. However, this approach is disconnected from the reality of small laboratory drug design, where building block resources are limited, making a notion of in-house synthesizability that uses already available resources highly desirable. In this work, we show a successful de novo drug design workflow generating active and in-house synthesizable ligands of monoglyceride lipase (MGLL). We demonstrate the successful transfer of CASP from 17.4 million commercial building blocks to a small laboratory setting of roughly 6,000 building blocks with only a decrease of -12% in CASP success. Moreover, we present a rapidly retrainable in-house synthesizability score, successfully capturing our in-house synthesizability without relying on external building block resources. We show that including our in-house synthesizability score in a multi-objective de novo drug design workflow, alongside a simple QSAR model, provides thousands of potentially active and easily in-house synthesizable molecules. Further, we highlight differences between general and in-house synthesizability scores and demonstrate potential problems with the out-of-distribution predictive performance of synthesizability scores on generated molecules. Finally, we experimentally evaluate the synthesis and biochemical activity of three de novo candidates using their CASP-suggested synthesis routes using only in-house building blocks. We find one candidate with evident activity, suggesting potential new ligand ideas for MGLL inhibitors while showcasing the usefulness of our in-house synthesizability score.